Ashish Phuyal

Ashish Phuyal

Auto-generated profile, based on publicly available information

Ashish Phuyal

Central Department of Chemistry, Institute of Science and Technology, Tribhuvan University, Kirtipur, 44618, Kathmandu, Nepal

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Journal of Institute of Science and Technology
Verified
Journal Article
Open access
NMNitesh Mallik
Nitesh Mallik
APAshish Phuyal
Ashish Phuyal
APAnuraj Phuyal
Anuraj Phuyal
NBNarendra Bhatta
Narendra Bhatta
AWAmar Waiba
Amar Waiba
AAAchyut Adhikari
Achyut Adhikari
Cancer remains a major global health challenge, and existing drugs have limited efficacy and adverse side effects. Key molecular regulators such as PARP1, ABL1, and CDK2 represent attractive targets for developing safer and more effective anticancer agents. MDA468 (Breast cancer), HCT-116 (Colon Cancer), CCRF (Leukemia), MDA-MB-435 (Melanoma), HOP-18 (non-small lung cancer), SKOV3 (Ovarian cancer), DU-145(Prostate cancer), and SN12K1 (Renal cancer) are cell lines studied in this paper. 216 phytoecdysteroids were computationally screened against these targets using molecular docking, ADMET profiling, and molecular dynamics simulations (MDS). Among them, Ecdysterone 22-benzoate 25-O-β-D-glycoside (PES 1) exhibited strong binding affinities of –11.3 kcal/mol (3L3M) and –9.1 kcal/mol (8H7H), while E-2-Deoxy-20-hydroxyecdysone 3-[4-(1-β-D-glucopyranosyl)]-caffeate (PES 44) demonstrated affinities of –9.3 kcal/mol (2A0C) and –9.2 kcal/mol (8H7H). Both complexes maintained RMSD values below 2 Å, and ADMET predictions further indicated favourable pharmacokinetic properties and low predicted toxicity. These findings suggest that PES 1 and PES 44 are promising phytoecdysteroid-based inhibitors with potential anticancer activity, warranting further extended simulations and experimental validation for their development into effective and safer anticancer therapeutics.

21 June 2025 in Journal of Institute of Science and Technology
Verified
Journal Article
Open access
PDF file
RKRanju Khatiwada
Ranju Khatiwada
ASAsmita Shrestha
Asmita Shrestha
KGKabita Gyawali
Kabita Gyawali
SUSiddha Raj Upadhyaya
Siddha Raj Upadhyaya
RPRezina Pradhan
Rezina Pradhan
NPNiranjan Parajuli
Niranjan Parajuli
Diabetic retinopathy (DR) is a harmful microvascular consequence of diabetes. Aldose reductase, an enzyme involved in the polyol pathway during hyperglycaemic conditions, is responsible for DR. Some commercially available enzyme inhibitors, such as epalrestat, zenarestat, etc., are recommended medications to control pathophysiology; nevertheless, most of them have been unable to satisfy the criteria to be considered a good drug choice. This study aims to explore a pool of secondary metabolites associated with their impressive anti-diabetic properties because they are related to undesirable side of the commercial medications currently on the market. We screened the most potent aldose reductase inhibitor via a thorough in silico study, which has been reported as good in vitro activity against human aldose reductase and rat lens aldose reductase. High-throughput computational techniques were applied to study the potency of 90 metabolites against target proteins. In silico pharmacokinetics and toxicity were evaluated for screened metabolites with binding energy less than -9.0 kcal/mol obtained through the molecular docking method. Among selected metabolites, myrciacitrin IV exhibited the best binding affinity (-9.1 kcal/mol and -11.8 kcal/mol) with both proteins and displayed the least band gap energy (3.379 eV), comparable with the standard drug. Further, molecular dynamics (MD) simulation and Molecular Mechanics Generalised-Born Surface Area (MM/GBSA) investigations confirm myrciacitrin IV as a potent drug candidate targeting aldose reductase.